top of page

Chemo Sensitivity Testing

Definition: Chemo Sensitivity Assay

from National Cancer Institute  (NCI)

“A laboratory test that measures the number of tumor cells that are killed by a cancer drug. The test is done after the tumor cells are removed from the body. A chemosensitivity assay may help in choosing the best drug or drugs for the cancer being treated. “


ChemoFx® Therapeutic Selection Marker

“Physicians have more than 20 standard of care therapies from which to choose that effectively treat gynecologic cancer. What they don’t have is a way to confirm which one will provide the best results for their individual patients. ChemoFx provides essential information that helps physicians determine the best treatment course for their patients based on personal tumor information: Proven to identify treatments that extend survival for patients with gynecologic cancer; Tests multiple chemotherapies on a patient’s cancer cells before treatment; Quantifies an individual’s probable tumor response to treatment; Identifies information on both sensitivity and resistance.


BioSpeciFx® Molecular Markers

BioSpeciFx assesses solid tumors at a molecular level using a select group of clinically relevant and validated cancer-related biomarker tests. When used in conjunction with ChemoFx to create a comprehensive tumor profile, physicians can confidently define and assess which of the multiple equivalent therapies has the highest potential for success: Provides intuitively organized panels by pathway and tumor type;

Informs decisions with clear, easy-to-understand results and summaries of clinical relevance; Comprises many guideline-recommended biomarkers supported by current research and literature from key opinion leaders in the oncology field; Can be used for any solid tumor type, including gynecologic, lung, breast, colon, and pancreatic.”

Rational Therapeutics

750 E. 29th Street, Long Beach, CA 90806


800.542.HELP (4357)

“When facing a diagnosis of cancer, there are many questions to be answered. Do I need chemotherapy or a targeted agent? What drugs or combinations are going to be best for me? How does my oncologist choose? For over 20 years, Rational Therapeutics has helped answer these important questions. Using 3D functional profiling to analyze each patient’s living cancer cells, our Ex Vivo Analysis of Programmed Cell Death (EVA-PCD®) selects from amongst many comparable choices those drugs or combinations most likely to work for you. This “real-time” analysis with results available within 7 days can provide potentially life-saving information. Our results have been shown to double response rates and can improve time-to-progression and survival. With these results, you and your oncologist will be equipped to make the most informed decision to treat YOUR cancer. “



Weisenthal Cancer Group
16512 Burke Lane Huntington Beach, CA 92647


“Increasingly, cancer physicians are turning away from the one-size-fits-all approach to chemotherapy drug selection. It has become apparent to physicians and researchers worldwide that better results can be achieved if cancer treatments are personalized, based upon specific biologic factors. These factors occur at the cellular level and are unique to each patient.  The two main approaches to what is called “personalized medicine” are cytometric profiling (performed by Weisenthal Cancer Group and, in other forms, by a very small number of other labs scattered throughout the world) and gene, or “molecular,” testing (available in some form from hundreds of large and small labs located virtually everywhere). Important differences in the two main approaches relate to precisely which biologic factors are tested, what technologies are used, and how expertly the technologies are applied.  It is highly probable that even your physician is not fully-aware of the differences which exist and how these differences dramatically affect the accuracy and usefulness of the information provided by the different tests.“

More Interesting Articles on Testing Advancements


Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept - PMC 

from National Center for Biotechnology Information  (NCBI)

Artificial intelligence in oncology: current applications and future perspectives

from the British Journal of Cancer (BJC)

Artificial Intelligence in Clinical Oncology: From Data to Digital Pathology and Treatment

from National Center for Biotechnology Information  (NCBI)


Artificial intelligence in gynecologic cancers: Current status and future challenges - A systematic review

from National Center for Biotechnology Information  (NCBI)


Diagnosing Ovarian and Other Cancers With Human and Artificial Intelligence

from The American Family Physician 

New phone app to test AI for improving care for ovarian cancer patients

from UC Davis Health 

bottom of page